Bernard Horn Comments on Transgene

Author's Avatar
Aug 07, 2014

Transgene (XPAR:TNG) dropped after Novartis declined to exercise an option to fund Transgene’s TG4010 targeted cancer immunotherapy for treatment of metastatic non-small cell lung cancer. Transgene is attempting to form another partnership by year-end, as there are three other interested parties.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Second Quarter 2014 Shareholder Letter.